CJC-1295 Side Effects: What Studies Report

CJC-1295 is a synthetic analogue of growth hormone–releasing hormone (GHRH) that was engineered for extended circulation. This page summarises what the published literature reports about its adverse-event profile, how long it remains detectable in the body, and how review papers characterise the risks of the combinations and handling practices discussed in non-clinical settings. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision or symptom.

What the Published Human Trial Reported

The primary controlled human evidence base is a 2006 early-phase study in healthy adults, in which researchers administered single escalating subcutaneous doses of 30, 60, 125 or 250 µg/kg of CJC-1295 and observed dose-dependent increases in growth hormone and IGF-I secretion (Teichman and colleagues, 2006). In that report, mean plasma growth hormone concentrations rose approximately 2- to 10-fold for six days or longer after a single dose, while IGF-I concentrations rose roughly 1.5- to 3-fold and remained elevated for about 9 to 11 days (Teichman and colleagues, 2006). The study also reported that growth hormone secretion remained pulsatile, that the estimated half-life of CJC-1295 was in the range of 5.8 to 8.1 days, and that no serious adverse reactions were observed during the trial, which included both single-dose and multiple-dose administration in healthy volunteers (Teichman and colleagues, 2006).

Reviews of the field emphasise how narrow that evidence base is. A 2026 structured narrative review of injectable peptides in sports medicine reported that growth-hormone secretagogues and GHRH analogues have not progressed to large or long-duration controlled safety trials, leaving long-term adverse-event rates undefined (JBJS Reviews, 2026). A 2026 review of performance-enhancing peptides acting on the GH–IGF-1 axis similarly reported a wide gap between the limited clinical evidence and the patterns of self-administration described outside clinical care (Frontiers in Endocrinology, 2026).

CJC-1295 Side Effects: What Studies Report

Because controlled trial data are sparse, most of what is published about adverse effects is extrapolated from the physiology of sustained growth hormone and IGF-I elevation. A 2026 review of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance reported that growth-hormone-axis agents carry risks including fluid retention, arthralgia, carpal tunnel–type nerve compression symptoms and impaired glucose tolerance (Sports Medicine, 2026).

Fluid retention, joint and nerve symptoms

A 2026 primer for orthopaedic and sports medicine physicians reported that injectable growth-hormone secretagogues have been associated with oedema, joint discomfort and paraesthesia consistent with excess GH signalling, and that such effects are the most commonly cited concerns in the literature (American Journal of Sports Medicine, 2026). A companion 2026 review of therapeutic peptides in orthopaedics reported comparable concerns and noted that many marketed peptides in this class remain unapproved for the indications for which they are promoted (JAAOS Global Research & Reviews, 2026).

Glucose handling and endocrine effects

A 2026 review of therapeutic peptides in aesthetic, metabolic and endocrine conditions reported that agents raising GH and IGF-I may alter insulin sensitivity and glucose metabolism, and called for monitoring frameworks that are currently absent for unapproved products (International Journal of Molecular Sciences, 2026). A 2026 gerontology review reported that theoretical concerns about long-term IGF-I elevation — including proliferative risk — have not been resolved by trials in older adults (Frontiers in Aging, 2026).

Product quality, sterility and counterfeit supply

Several reviews separated pharmacological risk from supply-chain risk. A 2026 review reported that peptides sold outside regulated pharmaceutical channels have shown variable purity, mislabelled content and sterility problems, making adverse events difficult to attribute to the labelled molecule (American Journal of Sports Medicine, 2026). The 2026 sports medicine review reported that research-use-only labelling does not imply any safety assessment for human use (Sports Medicine, 2026).

Self-reported experience in non-clinical settings

A 2016 netnographic analysis of online discussion among women using synthetic growth hormone products reported self-described dosing patterns, perceived effects and harms circulating in user communities, and the authors reported that such accounts sit outside clinical oversight (Substance Use & Misuse, 2016). These are self-reports, not measured adverse-event rates.

Does CJC-1295 or CJC-1295 with Ipamorelin Raise Blood Pressure: What Studies Report

The published human trial of CJC-1295 reported no serious adverse reactions and did not present blood pressure as a signal of concern (Teichman and colleagues, 2006). Review papers address the question indirectly: fluid retention and peripheral oedema are listed among GH-related adverse effects (Sports Medicine, 2026), and a 2026 review reported that cardiovascular and metabolic consequences of sustained GH–IGF-1 axis stimulation remain inadequately characterised in people who self-administer these compounds (Frontiers in Endocrinology, 2026). No trial in the verified literature measured blood pressure outcomes for a CJC-1295 plus ipamorelin combination.

How Long CJC-1295 Stays Measurable in the Body

The clearest published figure is pharmacokinetic: the study estimated a half-life of 5.8 to 8.1 days, with growth hormone elevations persisting six days or more and IGF-I elevations persisting roughly 9 to 11 days after a single dose (Teichman and colleagues, 2006). Those downstream hormone changes outlast the parent peptide, which is why review papers discuss biomarker-based rather than parent-drug detection in anti-doping contexts (Journal of Sports Medicine and Physical Fitness, 2026).

For blended products described as "CJC-1295 / ipamorelin", the verified literature contains no published pharmacokinetic study of the combination. Reviews reported that many peptide blends circulating outside clinical settings have never been characterised for absorption, half-life or clearance as mixtures (JBJS Reviews, 2026).

Combination and Stacking Questions in the Literature

CJC-1295 with ipamorelin

Ipamorelin acts on the ghrelin receptor rather than the GHRH receptor, and 2026 reviews reported that combinations of GHRH analogues with growth-hormone secretagogues are commonly described in non-clinical use but have not been evaluated in controlled human safety or efficacy trials (American Journal of Sports Medicine, 2026). A 2026 review reported that combining agents that act on the same hormonal axis amplifies the uncertainty around endocrine and metabolic effects rather than resolving it (Frontiers in Endocrinology, 2026).

Mixing two peptides in one syringe

No study in the verified literature examined the chemical compatibility, sterility or stability of CJC-1295 and ipamorelin combined in a single container. Reviews of compounded and research-labelled peptide products reported that sterility assurance, excipient composition and stability testing are frequently absent for these preparations, which is the context in which such questions arise (JAAOS Global Research & Reviews, 2026).

IGF-1 LR3 alongside CJC-1295

A 2026 review of GH–IGF-1 axis peptides reported that long-acting IGF-1 analogues used in performance settings lack human safety trials and raise concerns about hypoglycaemia and unopposed growth-factor signalling (Frontiers in Endocrinology, 2026). A 2026 critical review of peptide doping reported that stacking GH-axis agents with IGF-1 analogues is described in bodybuilding communities without supporting clinical data (Journal of Sports Medicine and Physical Fitness, 2026).

Retatrutide or other incretin agents alongside CJC-1295

No trial in the verified literature tested a multi-receptor incretin agonist together with CJC-1295 or ipamorelin. A 2026 review reported that metabolic peptides and GH-axis peptides are increasingly combined in aesthetic and weight-management contexts despite the absence of interaction data, and the authors reported that glucose-metabolism effects of GH-axis stimulation complicate interpretation of such combinations (International Journal of Molecular Sciences, 2026).

Alcohol, Timing, Vial Duration and Storage: What Studies Report

These practical questions are common, and the honest summary is that the verified literature does not answer most of them.

Where a question has no published answer, review authors reported that the absence of data is itself a finding: it means adverse effects and interactions cannot be quantified (JBJS Reviews, 2026).

Regulatory and Anti-Doping Context

A 2026 critical review reported that GHRH analogues and growth-hormone secretagogues are prohibited in sport and are widely encountered in recreational bodybuilding, often supplied through channels outside pharmaceutical regulation (Journal of Sports Medicine and Physical Fitness, 2026). The 2026 structured review reported that clinicians increasingly encounter patients using these products and that anti-doping and regulatory status form part of the risk picture alongside pharmacology (JBJS Reviews, 2026). CJC-1295 is not an approved medicine for the uses discussed in those reviews; material labelled research-use-only has not been assessed for human administration (Sports Medicine, 2026).

What the Evidence Does Not Establish

• Long-term adverse-event rates: no extended controlled trial of CJC-1295 appears in the verified literature, and reviews reported that durable safety data are missing (JBJS Reviews, 2026).
• Combination safety: reviews reported that stacked GH-axis regimens are undocumented in trials (Frontiers in Endocrinology, 2026).
• Cancer or cardiovascular outcomes: a 2026 review reported that long-term IGF-I elevation raises unresolved theoretical concerns (Frontiers in Aging, 2026).
• Product identity: tested samples from unregulated supply have shown purity and labelling problems (American Journal of Sports Medicine, 2026).

Readers looking for the underlying pharmacology — GHRH receptor signalling, how the drug affinity complex extends half-life, and how the 2006 trial was structured — will find that material in the CJC-1295 course rather than on this safety-focused page.

References

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (The American Journal of Sports Medicine, 2026)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review (The Journal of Sports Medicine and Physical Fitness, 2026)
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine (The American Journal of Sports Medicine, 2026)
• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions (Substance Use & Misuse, 2016)
• Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives (International Journal of Molecular Sciences, 2026)
• Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications (JBJS Reviews, 2026)
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging (Frontiers in Aging, 2026)
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Frontiers in Endocrinology, 2026)